Myelodysplastic syndrome with excess blasts-2

A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)

Also known as: MDS-EB-2, RAEB-2, RAEB-II, myelodysplastic syndrome with Excess blasts-2, refractory anaemia with excess blasts type 2, refractory anemia with excess blasts type 2

1861 clinical trials for this condition and its sub-types, 12 tagged with Myelodysplastic syndrome with excess blasts-2 itself.